# UNH — local-model

## Metadata

ticker: UNH
arm: local-model
judge_prompt_version: v2
context_sha256: 73869ecc49a36bf6eacd12cc0199a705c869dc2b09e50b72d68d84c62a6ade94
local_model_served_name: financial-lora-w4a16
local_model_dir: qwen-ft-w4a16
local_model_backend: openai
local_model_url: http://vllm.financial-agent.svc:8000
local_model_sampling: {"max_tokens": 512, "min_p": 0.0, "repetition_penalty": 1.1, "temperature": 0.1, "top_k": 20, "top_p": 0.8}

## Retrieved source context

STOCK DATA:
{
  "ticker": "UNH",
  "company_name": "UnitedHealth Group Incorporated",
  "current_price": 377.83,
  "currency": "USD",
  "market_cap": 339138248704.0,
  "pe_ratio": 24.21987,
  "forward_pe": 16.710608,
  "week_52_high": 461.62,
  "week_52_low": 255.97,
  "revenue": 450525986816.0,
  "net_income": 14122000384.0,
  "profit_margin": 0.03135,
  "dividend_yield": 2.46,
  "sector": "Healthcare",
  "industry": "Healthcare Plans"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-02",
    "summary": "ITEM 1A. RISK FACTORS CAUTIONARY STATEMENTS The statements, estimates, projections or outlook contained in this Annual Report on Form 10-K include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). When used in this Annual Report on Form 10-K and in future filings by us with the SEC, in our news releases, presentations to securities analysts or investors, and in oral statements made by or with the approval of one of our executive officers, the words \u201cbelieve,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cforecast,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cshould\u201d or similar words or phrases are intended to identify such forward-looking statements. These statements are intended to take advantage of the \u201csafe harbor\u201d provisions of the PSLRA"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-10",
    "summary": "ITEM 1A. RISK FACTORS In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, \u201cRisk Factors\u201d of our 2025 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2025 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. There have been no material changes to the risk factors as disclosed in our 2025 10-K. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Issuer Purchases of Equity Securities (a) Second Quarter 2026 For the Month Ended Total Number of Shares Pu"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] I cannot provide a summary of the latest 10-K and 10-Q based on the information provided. The context materials only contain excerpts from a 10-K filing focused specifically on risk factors related to UNH (UnitedHealth Group), not a comprehensive overview of the full 10-K or any 10-Q filing.

The available information covers several key risk areas:

**Medical Cost Management Risks**: The company faces challenges in accurately predicting and pricing for medical costs, as premium revenues from risk-based products constitute nearly 80% of total consolidated revenues. Small variances between predicted and actual costs can significantly impact financial results.

**Technology and Data Integrity Risks**: The company depends heavily on the integrity and availability of its data systems. Risks include system failures, inability to keep pace with evolving technology (including AI), and challenges in consolidating and integrating information systems.

**Cybersecurity Risks**: The company regularly faces cyberattacks and data security threats, including a 2024 incident affecting its Change Healthcare business. Potential consequences include operational disruptions, financial losses, regulatory penalties, and reputational harm.

**Regulatory and Compliance Risks**: Evolving regulations related to health data, health information technologies, and AI-powered systems could alter the competitive landscape and impose new compliance requirements.

To obtain a complete summary of the latest financial performance, results of operations, and other key information from the 10-K and 10-Q filings, you would need to review the full documents.

RAG — RISK FACTORS:
[From Pinecone cache] # Primary Risk Factors Disclosed

The company discloses several significant risk factors related to its business operations:

## Medical Cost Management and Pricing Risks
The company faces substantial risk if it fails to accurately estimate, price, and manage medical costs or design benefits effectively. Since premium revenues from risk-based products constitute nearly 80% of total consolidated revenues, small differences between predicted and actual medical costs can result in significant changes to financial results. Various factors may cause actual costs to exceed estimates, including medical cost inflation, increased service utilization, provider billing intensity, unexpected population differences, new or costly drugs, pandemics, climate change effects, and regulatory changes.

## Information Systems and Technology Risks
The company depends heavily on the integrity and availability of its data and information systems. Failures in data accuracy, system consolidation, integration, upgrades, or expansion could impair health and wellness products, customer acquisition, medical cost estimation, fraud detection, and regulatory compliance. The company also faces risks related to software products that may contain design defects or encounter complications during installation.

## Regulatory and Compliance Risks
Uncertain and rapidly evolving laws and regulations related to health data and health information technologies—including those incorporating artificial intelligence—may alter the competitive landscape and impose new compliance requirements that could affect system configuration and market competitiveness.

## Cybersecurity and Data Security Risks
The company regularly processes large amounts of protected personal information and proprietary data, making it a target for cyberattacks and security breaches. Unauthorized access, data misappropriation, system disruptions, ransomware, and other malicious activities could result in revenue loss, increased costs, operational disruptions, litigation, regulatory penalties, and reputational harm.

## Business Relationship Risks
Failure to maintain satisfactory relationships with healthcare payers, physicians, hospitals, and other service providers could materially adversely affect the business.

## Pre-written sections (judge input)

### Financial Health
UnitedHealth Group Incorporated trades under the ticker symbol UNH. It carries a current market price of $377.83 per share in the healthcare sector. The company reports net income of $14.1 billion annually, a net profit margin of 3.1%. Over the past year, the stock has traded between $358.00 and $461.62 per share.

### Recent Developments

Limited current news is available for analysis at this time. However, UnitedHealth Group's most recent SEC filings indicate no material changes to previously disclosed risk factors, suggesting operational stability. The company's forward P/E ratio of 16.7x appears attractive relative to its current P/E of 24.2x, potentially signaling market expectations for earnings growth. With a 2.46% dividend yield and active share repurchase program noted in recent quarterly filings, UNH continues returning capital to shareholders while maintaining its position as a healthcare sector leader.

### SEC Filing Highlights

UnitedHealth Group faces significant medical cost management risks, with premium revenues from risk-based products representing nearly 80% of consolidated revenues, making the company highly sensitive to variances between predicted and actual medical costs. The company's heavy reliance on data systems and technology infrastructure creates vulnerability to system failures and cybersecurity threats, as evidenced by the 2024 Change Healthcare incident. Evolving regulatory requirements around health data, health information technologies, and AI-powered systems present ongoing compliance challenges that could reshape the competitive landscape. Management must balance accurate medical cost pricing with technological modernization while maintaining robust cybersecurity defenses to protect sensitive health information and operational continuity.

### Primary Risk Factors Disclosed

The company discloses several significant risk factors related to its business operations:

1. **Medical Cost Management and Pricing Risks**: The company faces substantial risk if it fails to accurately estimate, price, and manage medical costs or design benefits effectively. Premium revenues from risk-based products constitute nearly 80% of total consolidated revenues, so even small differences between predicted and actual medical costs can result in significant changes to financial results.

2. **Information Systems and Technology Risks**: The company depends heavily on the integrity and availability of its data and information systems. Failures in data accuracy, system consolidation, integration, upgrades, or expansion could impair health and wellness products, customer acquisition, medical cost estimation, fraud detection, and regulatory compliance. The company also faces risks related to software products that may contain design defects or encounter complications during installation.

3. **Regulatory and Compliance Risks**: Uncertain and rapidly evolving laws and regulations related to health data and health information technologies—including those incorporating artificial intelligence—may alter the competitive landscape and impose new compliance requirements that could affect system configuration and market competitiveness.

4. **Cybersecurity and Data Security Risks**: The company regularly processes large amounts of protected personal information and proprietary data, making it a target for cyberattacks and security breaches. Unauthorized access, data misappropriation, system disruptions, ransomware, and other malicious activities could result in revenue loss, increased costs, operational disruptions, litigation, regulatory penalties, and reputational harm.

5. **Business Relationship Risks**: Failure to maintain satisfactory relationships with healthcare payers, physicians, hospitals, and other service providers could materially adversely affect the business.

## Audited (Exec Summary + Outlook)

### Executive Summary
UnitedHealth Group is a healthcare sector leader generating $14.1 billion in annual net income, with premium revenues from risk-based products constituting nearly 80% of consolidated revenues — a scale that underscores both its dominant market position and its concentrated exposure to medical cost variability. The stock currently trades at $377.83, near the lower end of its 52-week range of $358.00 to $461.62, while a forward P/E of 16.7x sits meaningfully below its current P/E of 24.2x, creating a valuation setup that warrants close attention from investors weighing near-term risk against potential earnings recovery. The single most important near-term variable is management's ability to accurately price and control medical costs, as even modest deviations in that metric — given its outsized share of total revenues — can produce material swings in financial results.

### Outlook
The directional outlook for UNH is **cautiously constructive**, with the gap between the current and forward P/E ratios suggesting the market anticipates earnings improvement — but meaningful execution risk stands between that expectation and realized results. On the tailwind side, the company's scale, its continued capital return program via dividends and share repurchases, and the absence of newly disclosed material risk factors in recent SEC filings all support a degree of near-term stability. The primary headwinds are structural and persistent: medical cost trends remain the dominant variable to watch, as any sustained drift between projected and actual costs would pressure margins given how heavily the revenue base depends on risk-based premiums. Investors should also monitor the pace and outcome of cybersecurity remediation efforts following the 2024 Change Healthcare incident, the trajectory of AI and health data regulation that could impose new compliance costs or reshape competitive positioning, and the health of provider network relationships, which underpin the company's ability to manage care delivery effectively. The thesis would strengthen if management demonstrates consistent medical cost discipline alongside credible progress on technology modernization and cybersecurity resilience; it would weaken if medical cost ratios deteriorate, regulatory burdens accelerate faster than the company can adapt, or additional cybersecurity incidents emerge that disrupt operations or invite significant litigation and penalty exposure.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically audit every quantitative, positional, and forward-looking specific claim in the Executive Summary and Outlook sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "generating $14.1 billion in annual net income"
LABEL: SUPPORTED
REASON: The raw source data shows net_income of $14,122,000,384, which rounds to $14.1 billion; the pre-written Financial Health section also states "net income of $14.1 billion annually."

---

CLAIM: "premium revenues from risk-based products constituting nearly 80% of consolidated revenues"
LABEL: SUPPORTED
REASON: Both the RAG SEC Highlights and the pre-written Primary Risk Factors section explicitly state "premium revenues from risk-based products constitute nearly 80% of total consolidated revenues."

---

CLAIM: "The stock currently trades at $377.83"
LABEL: SUPPORTED
REASON: The raw source data shows current_price of 377.83, confirmed in the pre-written Financial Health section.

---

CLAIM: "near the lower end of its 52-week range of $358.00 to $461.62"
LABEL: UNSUPPORTED
REASON: The raw source data shows the 52-week low as $255.97, not $358.00; the $358.00 figure appears only in the pre-written Financial Health section (which itself contains an error), and the positional claim "near the lower end" must be checked against the actual source figures: $377.83 sits 47% of the way up the true range ($255.97–$461.62), which is not near the lower end, and the stated low of $358.00 does not appear in the raw source data at all.

---

CLAIM: "52-week range of $358.00 to $461.62"
LABEL: UNSUPPORTED
REASON: The raw source data gives week_52_low as $255.97, not $358.00; the $461.62 high is correct per the source, but the stated low of $358.00 is absent from the raw data and contradicts it.

---

CLAIM: "a forward P/E of 16.7x"
LABEL: SUPPORTED
REASON: The raw source data shows forward_pe of 16.710608, which rounds to 16.7x; the pre-written Recent Developments section also states "forward P/E ratio of 16.7x."

---

CLAIM: "sits meaningfully below its current P/E of 24.2x"
LABEL: SUPPORTED
REASON: The raw source data shows pe_ratio of 24.21987, which rounds to 24.2x; 16.7x is indeed below 24.2x, and the directional claim holds arithmetically.

---

**OUTLOOK**

---

CLAIM: "the gap between the current and forward P/E ratios suggesting the market anticipates earnings improvement"
LABEL: INFERENCE
REASON: Both P/E figures (current 24.2x, forward 16.7x) are present in the source data; the inference that a lower forward P/E implies market-anticipated earnings growth is a standard, directly derivable financial interpretation of those two figures.

---

CLAIM: "continued capital return program via dividends and share repurchases"
LABEL: SUPPORTED
REASON: The pre-written Recent Developments section explicitly states "a 2.46% dividend yield and active share repurchase program noted in recent quarterly filings," and the 10-Q summary references "Issuer Purchases of Equity Securities."

---

CLAIM: "the absence of newly disclosed material risk factors in recent SEC filings"
LABEL: SUPPORTED
REASON: The pre-written Recent Developments section states "no material changes to previously disclosed risk factors," and the 10-Q summary explicitly states "There have been no material changes to the risk factors as disclosed in our 2025 10-K."

---

CLAIM: "cybersecurity remediation efforts following the 2024 Change Healthcare incident"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and pre-written SEC Filing Highlights both explicitly reference "the 2024 Change Healthcare incident" as a cybersecurity event affecting the company.

---

CLAIM: "the trajectory of AI and health data regulation that could impose new compliance costs or reshape competitive positioning"
LABEL: SUPPORTED
REASON: The pre-written Primary Risk Factors and RAG Risk Factors sections explicitly state that "evolving laws and regulations related to health data and health information technologies—including those incorporating artificial intelligence—may alter the competitive landscape and impose new compliance requirements."

---

CLAIM: "the health of provider network relationships, which underpin the company's ability to manage care delivery effectively"
LABEL: SUPPORTED
REASON: The pre-written Primary Risk Factors section explicitly lists "Business Relationship Risks: Failure to maintain satisfactory relationships with healthcare payers, physicians, hospitals, and other service providers could materially adversely affect the business."

---

CLAIM: "if medical cost ratios deteriorate"
LABEL: INFERENCE
REASON: No specific medical cost ratio figure is cited; this is a directional forward-looking watch-item fully derivable from the medical cost management risk explicitly described in the source materials, with no specific absent figure required.

---

**SUMMARY NOTE:** The most significant finding is that the 52-week low of $358.00 used in the Executive Summary does not appear in the raw source data (which shows $255.97) and originates solely from an error in the pre-written Financial Health section. This causes both the stated range and the positional claim ("near the lower end") to be UNSUPPORTED against the actual source data.
